RecruitingNCT07419893

Germline Genetic Testing of the TP53 Gene

Germline Genetic Testing of the TP53 Gene: Identification, Characterization, and Management of Patients and Families at High Risk of Cancer

Sponsor

European Institute of Oncology

Enrollment

1,940 participants

Start Date

Jan 29, 2026

Study Type

OBSERVATIONAL

Conditions

TP53 Gene Mutation Multi-Gene Transcriptional Profiling TP53 Gene Germline Mutation Carrier

Summary

This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with multi-gene transcriptional profiling, tp53 gene germline mutation carrier, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Istituto Europeo di Oncologia

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07419893

Related Trials

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

NCT045416543 locations

Oral-ATO for TP53-mutated Myeloid Malignancies

NCT067781871 location